SHP 623

Drug Profile

SHP 623

Alternative Names: rC1-INH - Shire; Recombinant-C1-esterase-Shire; SHP623

Latest Information Update: 21 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shire
  • Class Complement C1 inactivator proteins; Recombinant proteins
  • Mechanism of Action Complement C1 inhibitors; Complement system protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hereditary angioedema

Most Recent Events

  • 01 Dec 2016 Shire completes a phase I trial in Hereditary angioedema (In volunteers) in USA (SC and IV) (NCT02663687)
  • 01 Feb 2016 Phase-I clinical trials in Hereditary angioedema (In volunteers) in USA (SC and IV) (NCT02663687)
  • 01 Jan 2016 Preclinical trials in Hereditary angioedema in Ireland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top